Albumin-bound NP with rapamycin (known as nab-rapamycin) in combination with pazopanib hydrochloride is in the clinical trial (phase1/2 and 57 patients) which is expected to halt the tumour growth by blocking the growth of enzymes that target advanced non-adipocytic soft tissue, solid tumours, glioma, and glioblastoma [237]. This evidence concerns the gene ALB and glioma.